CGRP Inhibitors for Migraine Linked to Reduced Glaucoma Risk

The use of calcitonin gene-related peptide (CGRP) inhibitors to treat adults with migraine is linked to a 25% lower risk for glaucoma than the use of non-CGRP inhibitors, a new study shows.
Medscape Medical News